VYDURA Trademark

Trademark Overview


On Friday, July 8, 2022, a trademark application was filed for VYDURA with the United States Patent and Trademark Office. The USPTO has given the VYDURA trademark a serial number of 97495182. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Monday, February 12, 2024. This trademark is owned by Biohaven Pharmaceutical Ireland DAC. The VYDURA trademark is filed in the Pharmaceutical Products category with the following description:

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclero...
vydura

General Information


Serial Number97495182
Word MarkVYDURA
Filing DateFriday, July 8, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateMonday, February 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 11, 2023

Trademark Statements


Goods and ServicesMedicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine-adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 13, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiohaven Pharmaceutical Ireland DAC
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressRingaskiddy CountyCor
IE

Party NameBiohaven Pharmaceutical Ireland DAC
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressRingaskiddy CountyCor
IE

Trademark Events


Event DateEvent Description
Tuesday, February 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 12, 2024SOU EXTENSION 1 GRANTED
Monday, February 12, 2024SOU EXTENSION 1 FILED
Monday, February 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, September 5, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023PUBLISHED FOR OPPOSITION
Wednesday, June 21, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 4, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 4, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 4, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, May 3, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, May 3, 2023TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Wednesday, May 3, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 3, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, May 3, 2023WITHDRAWAL OF ATTORNEY GRANTED
Wednesday, May 3, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Thursday, December 8, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, December 8, 2022LETTER OF SUSPENSION E-MAILED
Thursday, December 8, 2022SUSPENSION LETTER WRITTEN
Wednesday, December 7, 2022ASSIGNED TO EXAMINER
Thursday, October 27, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 27, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 27, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 27, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 27, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, July 13, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 12, 2022NEW APPLICATION ENTERED